atorvastatin
atorvastatin: developed by 2 companies · 11 clinical trials tracked · 5 FDA decisions.
atorvastatin evidence translation
What we can confirm
5 FDA records · 11 tracked trials
What it means
What to watch
Prepared research question
What is verified about atorvastatin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 7 study sponsors
Related indications
Development Pipeline (2)
| Company | Phase |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) | Approved |
| Teva Pharmaceutical Industries Limited (TEVA) | Approved |
Clinical Trials (11)showing 10 most recent
A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of UBT251 on the Pharmacokinetics of Single Oral Doses of Metformin, Warfarin, Atorvastatin, and Digoxin in Overweight or Obese Participants.
Primary endpoint: Area under plasma concentration-time curve of metformin (AUC0-τ) and S-warfarin, R-warfarin (AUC0-t, AUC0-∞)
An Open-label, Fixed-sequence Study to Assess the Effect of Elecoglipron on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Participants
Primary endpoint: Area under concentration-time curve from time 0 to infinity (AUCinf) of atorvastatin
A Multi-Center, Randomized, Open-label, Parallel, Controlled Phase Ⅳ Clinical Trial to Evaluate the Effect of Inclisiran on Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarction and Elevated Low-density Lipoprotein Cholesterol
Primary endpoint: Change in percent atheroma volume (PAV)
EpisodicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Episodic Migraine
Primary endpoint: Number of migraine days
An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or Obesity
Primary endpoint: AUC0-72hours,atorv,SD: Area under the atorvastatin plasma concentration-time curve from time 0 to 72 hours after a single dose of atorvastatin without CagriSema exposure and at CagriSema steady state
A Study to Evaluate the Effect of Daily Doses of Obicetrapib Tablets on the Pharmacokinetics of Atorvastatin Calcium Tablets or Rosuvastatin Calcium Tablets in Healthy Adult Subjects
Primary endpoint: Measure atorvastatin/rosuvastatin levels in the blood
Vascular Endothelial Dysfunction in Sleep Apnea
Primary endpoint: Circulating levels of Angiopoietin-2 after 4 weeks of atorvastatin vs. placebo therapy
A Pilot Study of Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy
Primary endpoint: Interference in pregnancy progress
Targeting Cerebrovascular Reactivity for Precision Medicine: Pilot Trial of Atorvastatin
Primary endpoint: Change of MRI whole brain cerebrovascular reactivity (wbCVR)
Clinical Trial to Determine the Effects of Statins on Brain Health - STAREE-Mind Imaging Substudy
Primary endpoint: Free water
FDA Decisions5 records
Frequently asked questions
Who is developing atorvastatin?
atorvastatin is being developed by DR REDDYS LABORATORIES LTD, Teva Pharmaceutical Industries Limited.
How many clinical trials involve atorvastatin?
BioSniper tracks 11 clinical trials involving atorvastatin.
What is atorvastatin's latest FDA decision?
The most recent tracked FDA decision for atorvastatin is Approval for 1 INDICATIONS AND USAGE Atorvastatin calcium tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive , dated November 13, 2025.